ClinicalTrials.gg
Not yet recruitingNCT07941726GABAPLASTUpdated Nov 17, 2026

Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke

An interventional study of Baclofen and Oxazepam in Stroke, Brain Plasticity and GABAergic Modulation, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Stroke by University Hospital, Toulouse — 9 open to participants now, 9 under way, none of them phase 3. Stroke · University Hospital, Toulouse.

Planned enrollment
17th of 20
12 · median 21
Started
2026
with 4 others
No phase
18 of 23
8 open now
Registered
23rd of 23
by date

Among the 23 studies in Stroke by University Hospital, Toulouse, this one is the 17th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, and was the 23rd registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 23 studies in Stroke by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Stroke by University Hospital, Toulouse, or all of them as a file.
02

Study summary

The GABAPLAST study explores how commonly prescribed GABAergic drugs prescribed during post-stroke rehabilitation affect cortical plasticity and motor learning capacity. Using a multiple-baseline single-case design, the study evaluates the effects of Baclofen, Oxazepam, and Gabapentin in subacute stroke patients according to their clinical indication. Cortical plasticity capacity is measured with transcranial magnetic stimulation and Paired Associative Stimulation (TMS/PAS). The study aims to determine whether these drugs interfere with or preserve brain plasticity during recovery.

Read the detailed description

Scientific rationale Functional recovery after stroke relies on neuroplasticity, the brain's ability to reorganize neural connections. During the subacute phase, high synaptic plasticity allows efficient motor relearning, but GABAergic inhibition may reduce these mechanisms. Several animal and human studies suggest that increased GABAergic activity limits long-term potentiation of plasticity (LTP-like) and motor learning. Baclofen (GABA-B agonist), Oxazepam (GABA-A agonist), and Gabapentin (GABA modulator) are routinely prescribed to treat spasticity, anxiety, or neuropathic pain after stroke, yet their neurophysiological effects remain unclear. GABAPLAST aims to provide the first controlled experimental evidence of their direct influence on cortical plasticity and implicit motor learning in subacute stroke patients.

Treatment/strategy/procedure and follow up

The study comprises 26 repeated assessment sessions performed five times per week, from Monday to Friday, over approximately six weeks. Each participant will receive one of the following medications according to their clinical indication: oxazepam for anxiety; baclofen for spasticity; gabapentin for neuropathic pain. Each participant will undergo two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication;
  • Phase B: phase with exposure to the study medication, including dose titration and treatment at the clinically appropriate dose.

The duration of Phase A will be randomized to 6, 9 or 12 repeated assessments. Phase B will comprise 20, 17 or 14 assessments, respectively, so that each participant completes a total of 26 assessments.

During Phase A, participants in the oxazepam SCED may receive appropriate non-pharmacological usual-care interventions, such as psychological support, relaxation techniques, sophrology or psychotherapy, according to their clinical needs. If immediate pharmacological treatment becomes necessary, the participant will discontinue the study and receive the appropriate treatment without delay.

Medication doses will be adjusted by the investigator according to usual clinical practice, treatment efficacy and tolerability, within the limits defined in the relevant Summary of Product Characteristics and the dose-titration schedules specified in the protocol. Dose changes, dates and reasons for adjustment will be documented in the electronic case report form.

Each assessment session will include: tablet-based motor learning tasks: the Serial Reaction Time Task and Target Jump Task; TMS/PAS assessment of cortical excitability and plasticity; standardized collection of adverse events.

03

Conditions studied

  • Stroke
  • Brain Plasticity
  • GABAergic Modulation
  • Motor Learning
  • Spasticity
  • Anxiety
  • Neuropathic Pain

Keywords

  • stroke rehabilitation
  • brain plasticity
  • GABAergic drugs
  • baclofen
  • oxazepam
  • gabapentin
  • TMS
  • Paired Associative Stimulation
  • motor learning
  • Single-Case Experimental Design
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) with ischemic or hemorrhagic stroke in the subacute phase (2 weeks-6 months)
  • Non-urgent clinical indication for oxazepam, baclofen or gabapentin, with the protocol-defined treatment initiation interval considered medically acceptable by the investigator
  • PGI-S score of at least 2 for the symptom leading to treatment prescription
  • Ability to understand and consent (BDAE score >3)
  • Brain MRI available for neuronavigation
  • No motor impairment in the non-paretic hand
  • Affiliation with a national health insurance system
  • Free, informed and written signed by the participant and the investigator (at the latest on the day of inclusion and before any review required by the research).

Exclusion criteria

Exclusion Criteria:

  • Current or recent treatment, within the previous 7 days, with a gabaergic drug of interest (oxazepam, gabapentin, baclofen)
  • Current or recent treatment, within the previous 7 days, with any prohibited treatment (benzodiazepine, Z-drug, morphine, pregabalin, sedative antipsychotic or barbiturate).
  • History of neurological disorders other than stroke, for example: neurodegenerative disease, multiple sclerosis, epilepsy, brain tumour, hydrocephalus.
  • History of severe psychiatric conditions, such as schizophrenia or bipolar disorder
  • Need for immediate initiation of the planned medication

    • Oxazepam: severe respiratory failure, untreated sleep apnoea syndrome, severe acute or chronic hepatic impairment, myasthenia gravis, to oxazepam or any , galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
    • Baclofen: hypersensitivity to baclofen or any excipient, wheat allergy, or coeliac disease
    • Gabapentin: hypersensitivity to gabapentin or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
  • Presence of a psychoactive substance dependence
  • Pregnancy or breast-feeding
  • Skin disorder in the stimulated hand indicating the placement of electromyographic collection or stimulation electrodes
  • Medical for the performance of MSDs according to the TMS safety questionnaire
  • Presence of a major peripheral neuromuscular disorder (e.g. severe motor neuropathy) making the interpretation of PEM unreliable.
  • Guardianship, curatorship, safeguarding of justice
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Baclofen SCED

    The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, baclofen intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

    Drug: Baclofen

  • Experimental
    Oxazepam SCED

    The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, oxazepam intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

    Drug: Oxazepam

  • Experimental
    Gabapentin SCED

    The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, gabapentin intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

    Drug: Gabapentin

Interventions

  • DrugBaclofen

    Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases: * Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation. * Phase B: phase with exposure to baclofen, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments.

  • DrugOxazepam

    Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases: * Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation. * Phase B: phase with exposure to oxazepam, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments

  • DrugGabapentin

    Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases: * Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation. * Phase B: phase with exposure to gabapentin, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments

06

What researchers measure

Primary outcomes

  1. Brain plasticity

    It will be assessed by the change in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between the pre-PAS and post-PAS measurements. The variation represents the degree of brain plasticity induced by the PAS protocol during a session. It will be done during all the assessments of phase A and phase B.

    Time frame: 6 weeks

Secondary outcomes

  1. Cortical excitability: Membrane excitability of neurons in the motor cortex

    It will be assessed by the Resting Motor Threshold (RMT), defined as the minimum stimulation intensity, expressed as a percentage of the Maximum Stimulator Output (MSO), that elicits at least 5 motor evoked potentials (PEM) ≥ 50 µV in 10 trials. It will be done during each session of phase A and phase B (except on the last day of each phase).

    Time frame: 6 weeks

  2. Cortical excitability: Changes in cortical membrane excitability induced by the PAS protocol

    It will be assessed by the change (Δ) in RMT induced by the PAS protocol, expressed as the percentage change between the RMT measured immediately after PAS and the RMT measured before PAS. It will be done during each session of phase A and phase B (except on the last day of each phase).

    Time frame: 6 weeks

  3. Cortical excitability: Overall response of the corticospinal tract

    It will be assessed by the PEM amplitude at the RMT, defined as the "peak-to-peak" average (µV) calculated from a series of 20 PEMs recorded at the RMT. It will be done during each session of phase A and phase B (except on the last day of each phase).

    Time frame: 6 weeks

  4. Cortical excitability: Conduction and functional integrity of corticospinal tracts

    It will be assessed by the PEM latency at the RMT, defined as the time (ms) between the magnetic pulse and the onset of the muscle response, averaged over 20 trials. It will be done during each session of phase A and phase B (except on the last day of each phase).

    Time frame: 6 weeks

  5. Motor learning performance: general learning effect assessed by SRTT

    The general learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence). During the SRTT, the participant must slide their finger from one position to another as quickly as possible, in response to a visual stimulus appearing at one of the four locations on the screen. In the sequenced condition, a sequence of 8 movements is repeated six times per block, while in the random condition, the 48 positions appear in a random order. The blocks follow the same alternation (R-S-S-S-R-S), allowing for the isolation of effects related to the learning of motor sequences.

    Time frame: 6 weeks

  6. Motor learning performance: specific learning effect assessed by SRTT

    The specific learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence).

    Time frame: 6 weeks

  7. Motor learning performance: retention assessed by SRTT

    The retention will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random).

    Time frame: 6 weeks

  8. Motor learning performance: general learning effect assessed by Target Jump tasks

    The general learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence). During the Target Jumps tasks, the participant must return their finger to the lower center of the screen before each trial, then slide it toward the target that appears. The target shifts a few centimeters as the participant begins the movement. The blocks alternate according to the pattern R-S-S-S-R-S, with random or systematic shifts, allowing for the exploration of visuomotor adaptation abilities.

    Time frame: 6 weeks

  9. Motor learning performance: specific learning effect assessed by Target Jump tasks

    The specific learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence).

    Time frame: 6 weeks

  10. Motor learning performance: retention assessed by Target Jump tasks

    The retention will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random).

    Time frame: 6 weeks

  11. Severity of the symptom that lead to initial treatment prescription

    It will be reported by the patient using the Patient Global Impression of Severity PGI-S completed at inclusion, on the last day of phase A and last day of phase B. This scale ranges from 1 ("no discomfort/pain/anxiety") to 4 ("severe"). Each patient will complete only one PGI-S form, corresponding to the symptom being treated by the study drug.

    Time frame: 6 weeks

  12. Safety of participants

    It will be assessed by the spontaneous report on adverse events, assessed at each session.

    Time frame: 6 weeks

07

Study locations

1 site
  • Raymonde Fournet Purpan Hospital - Toulouse University Hospital
    Toulouse, 31 059, France
    • Emmeline Montané, MD · Contactmontane.e@chu-toulouse.fr · 05 61 77 90 02
    • Emmeline Montané, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2028, 18 months later.

Of 3,119 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 18 months is below that.

Counting every sponsor, half of 3,263 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941726
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Emmeline Montané, MD
Contact
montane.e@chu-toulouse.fr
05 61 77 90 02 ext. +33
Emmeline Montané, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion